Shots:
Eli Lilly has entered into a definitive agreement to acquire CrossBridge Bio, incl. its synergistic dual payload platform for the development of differentiated therapeutics
As per the deal, Lilly will acquire CrossBridge Bio for ~$300M in cash, incl. an upfront payment & a subsequent milestone payment
CrossBridge Bio is advancing CBB-120, a TROP2-targeting TOP1i/ATRi…
Shots:
Welcome to the 2025 edition of Know Your Investor, spotlighting leading venture capital firms driving innovation in healthcare.
This edition features Alexandria Venture Investments, a firm committed to supporting disruptive life science companies that aim to improve human health.
In 2024, the firm invested approximately $2.7B across six public and private funding rounds, adding…

